Crinetics Palsonify (Paltusotine) Up to 2-Year PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Data at ENDO 2026 on June 14
Crinetics Pharmaceuticals (Nasdaq: CRNX) will present an oral abstract Sunday June 14 (1:45-3:15 PM CT, Room W183BC) covering up to two years of efficacy and pooled safety data from the Palsonify (once-daily oral paltusotine) PATHFNDR-1 and PATHFNDR-2 open-label extensions in acromegaly, plus long-term combination data with cabergoline from the ACROBAT Advance trial. The presentation lands four days after Camurus's second Complete Response Letter on Oclaiz (CAM2029), the rival monthly subcutaneous octreotide depot, leaves the US acromegaly market with only one approved next-generation entrant (Palsonify, approved September 2025) through at least H1 2027. Crinetics will also present six total abstracts at ENDO including Phase 2 atumelnant data in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.